| P50 | author | Tadahiko Shien | Q53517862 |
| | Sadako Akashi-Tanaka | Q89879422 |
| | Masashi Ando | Q90096247 |
| | Noriyuki Katsumata | Q90594060 |
| | Takashi Hojo | Q92052509 |
| | Chikako Shimizu | Q92609313 |
| | Yasuhiro Fujiwara | Q99517112 |
| | Takayuki Kinoshita | Q116284911 |
| | Tsutomu Kohno | Q117226660 |
| | Kunihiko Seki | Q117226662 |
| | Kunihisa Miyakawa | Q117226665 |
| P2093 | author name string | Hiroyoshi Doihara | |
| | Naruto Taira | |
| P2860 | cites work | Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation | Q35588886 |
| | Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. | Q36901398 |
| | Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. | Q40675977 |
| | Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma | Q44414131 |
| | Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response | Q44433157 |
| | Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy | Q44732056 |
| | The use of contrast-enhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery | Q44743741 |
| | Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophosphamide followed by docetaxel in patients with breast cancer | Q45031042 |
| | Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer | Q45287928 |
| | Breast conservative surgery: is it appropriate for locally advanced breast cancer following downstaging by neoadjuvant chemotherapy? A pathological assessment | Q46725896 |
| | High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. | Q46788885 |
| | Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study. | Q53606660 |
| | HER2 and Response to Paclitaxel in Node-Positive Breast Cancer | Q57578418 |
| | Prognostic significance of accumulation of gene and chromosome alterations and histological grade in node-negative breast carcinoma | Q74273072 |
| | The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile | Q75344740 |
| | Effect of preoperative chemotherapy on the outcome of women with operable breast cancer | Q77093352 |
| | Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18 | Q77438388 |
| | A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer | Q77713875 |
| | Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution | Q83894535 |
| P433 | issue | 1 | |
| P304 | page(s) | 44-51 | |
| P577 | publication date | 2009-01-01 | |
| P1433 | published in | World Journal of Surgery | Q15763279 |
| P1476 | title | Clinicopathological features of tumors as predictors of the efficacy of primary neoadjuvant chemotherapy for operable breast cancer | |
| P478 | volume | 33 | |